Hims & Hers Health is trading 9.5% higher at €26.18 as investors extend a recovery following a sharp selloff triggered by an FTC lawsuit regarding marketing and subscription-cancellation practices.
- Shares previously plummeted 10.51% to €22.48 on July 29, 2026, before beginning to stabilize as regulatory-driven fears eased.
- The stock's upward momentum is supported by a broadly positive market backdrop, with major U.S. indices all trading higher.